LISA Life Science Austria
A profitable destination: This simple formula sums up what makes Austria a compelling opportunity for international companies. For such investors, the obvious choice is to capitalize on Austria’s know-how, commitment to quality, first-rate technology and state-of-the-art infrastructure – not to mention its combination of EU membership and proximity to Eastern Europe. They decide for certain success – and thereby for Austria, a country to feel good.
The Vienna region is a major focus for “red biotechnology”, and a range of global players have located their Austrian subsidiaries here, or set up their own laboratories as spin-offs. Close cooperation with university clinics, as in Innsbruck, also sets international standards, not least in the field of cell therapy.
“White biotechnology” is concentrated in Styria, and there are also exciting innovations in Vienna. Lower and Upper Austria are developing analytical and therapeutic methods in “green biotechnology” that are applied worldwide, and even “blue biotechnology” is now putting down roots in Austria.